Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression.
Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.
Location: United States, Maryland, Germantown
Employees: 1-10
Total raised: $40M
Founded date: 2013
Investors 3
Date | Name | Website |
- | T1D Fund | t1dfund.or... |
- | TEDCO | tedcomd.co... |
- | Frazier Li... | frazierls.... |
Funding Rounds 1
Date | Series | Amount | Investors |
23.02.2021 | Series C | $40M | - |
Mentions in press and media 5
Date | Title | Description | Source |
10.08.2021 | Seraxis appoints Shelley Hartman, Jerry Baty and MJ Choi to ... | GERMANTOWN, Md., Aug. 10, 2021 /PRNewswire/ -- The regenerative medicine company Seraxis today ann... | prnewswire... |
23.02.2021 | Capstone Headwaters Advises Seraxis on $40M Series C Financi... | Capstone Headwaters, a leading middle market investment banking firm, advised Seraxis, Inc., a biote... | citybizlis... |
10.02.2021 | Seraxis Snags $40M in Series C Funding | GERMANTOWN, MD, Seraxis announced a $40M Series C private financing round led by Eli Lilly and Com... | vcnewsdail... |
09.02.2021 | Seraxis Closes $40M Series C Financing Round | William Rust, PhD, Chief Executive Officer and Founder, Seraxis Seraxis, a Germantown, Md.-based bi... | finsmes.co... |
09.02.2021 | Seraxis Closes $40M Series C | Seraxis, a biotech company developing a cell replacement therapy for insulin-dependent diabetes toda... | citybizlis... |